HER2-negative Breast Cancer – A Pathologist’s Perspective

As the treatment landscape for breast cancer evolves, so too must the interpretation of pathology results. For HER2-negative breast cancer (IHC 0, 1+, and 2+ [ISH-negative]), interpretation can have a significant impact on treatment decisions and patient prognosis. Professor Johan Hartman shares his experience and insights.